Can Anyone Take Ozempic to Lose Weight? Medical Eligibility

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, not everyone can safely take Ozempic for weight loss. FDA approval for weight management (Wegovy) requires a BMI of 30 or higher, or BMI of 27+ with weight-related comorbidities like hypertension or type 2 diabetes. Medical history, kidney function, thyroid status, and contraindications significantly narrow who qualifies.

Understanding your individual medical profile and metabolic predispositions can help you and your provider make a more informed decision about whether GLP-1 therapy is appropriate for you. PlexusDx focuses on precision assessment to support these conversations, ensuring treatment aligns with your clinical needs and genetic context.

Medical Eligibility Criteria for GLP-1 Weight Loss Treatment

GLP-1 receptor agonists for weight management require specific baseline criteria. FDA-approved semaglutide (Wegovy) mandates BMI ≥30 kg/m² or BMI ≥27 with weight-related conditions. Type 2 diabetes or hypertension presence can lower BMI thresholds. Providers assess baseline kidney function and cardiovascular stability before initiating therapy.

Beyond BMI, providers evaluate metabolic markers including fasting glucose, lipid profiles, and inflammatory markers. Individual response patterns vary significantly based on baseline metabolic state. Some patients with metabolically healthy obesity may respond differently than those with insulin resistance or prediabetes.

Absolute and Relative Contraindications in GLP-1 Selection

Certain medical conditions preclude GLP-1 use entirely. Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2, acute pancreatitis, and severe diabetic retinopathy represent absolute contraindications. Relative contraindications—including pregnant/nursing status, active gallbladder disease, and severe renal impairment—require careful provider risk-benefit analysis before proceeding.

Contraindication Type	Clinical Condition	Provider Action
Absolute	Personal/family history medullary thyroid cancer	GLP-1 therapy contraindicated
Absolute	Multiple Endocrine Neoplasia type 2	Avoid all GLP-1 agonists
Absolute	Recent acute pancreatitis episode	Screen for chronic pancreatitis; assess risk
Relative	eGFR <15 mL/min/1.73m²	Enhanced monitoring; dose considerations
Relative	Pregnancy or breastfeeding	Defer initiation; discuss timing
Relative	Active thyroid nodule or nodular goiter	Baseline ultrasound; provider discussion

Metabolic and Genetic Factors Influencing Treatment Response

Emerging research shows GLP-1 efficacy varies based on baseline insulin resistance, inflammation markers, and genetic predispositions in peptide signaling pathways. Variants in GLP1R, GIPR, FTO, and MC4R genes may influence appetite regulation, satiety signaling, and weight loss trajectory. These predispositions can provide context for provider discussions about expected response patterns.

Individuals with high FTO risk alleles may experience greater baseline weight predisposition but can still respond well to GLP-1 therapy with appropriate dosing and lifestyle support. GIPR variants may correlate with differing glucose control responses. A genetic assessment can help providers tailor expectations and monitoring strategies to individual metabolic architecture.

Safety Monitoring and Who Should Seek Provider Guidance First

Anyone with a history of pancreatitis, thyroid disorders, kidney disease, or cardiovascular events should obtain provider clearance before starting GLP-1 therapy. Patients over 65, those on multiple medications, and individuals with a family history of medullary thyroid cancer require enhanced baseline assessment and ongoing monitoring protocols.

Compounded GLP-1 options—including semaglutide and tirzepatide from licensed 503A pharmacies—require the same clinical oversight as branded medications. Your provider should evaluate kidney function, baseline metabolic markers, and contraindications before any initiation, and adjust dosing based on your individual tolerability and response.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1 signaling pathways—specifically variants in GLP1R, GIPR, FTO, and MC4R genes that relate to appetite regulation and weight response. This information should be interpreted with your qualified healthcare provider to support more personalized treatment discussions.

The genetic test reveals predispositions in peptide genetic pathways, not exact medication response or guaranteed outcomes. A result showing FTO risk variants, for example, indicates increased genetic weight predisposition but does not predict whether you will or will not respond to GLP-1 therapy. Genetic context works alongside medical history, metabolic labs, and clinical judgment.

Armed with both your genetic predisposition profile and baseline clinical assessment, you and your provider can have a more informed conversation about whether GLP-1 treatment aligns with your health needs, expected response patterns, and monitoring approach. PlexusDx's compounded options (semaglutide from $179/month, tirzepatide from $229/month) offer flexibility once medical eligibility is confirmed.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.